Ipsen: ASCO 2022: New Cabometyx Data Show Encouraging Result

COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase

Related Keywords

Japan , Serbia , Saclay , France General , France , Kazakhstan , Australia , Taiwan , United States , Shanghai , China , United Kingdom , Hong Kong , Paris , Brazil , Russia , Ukraine , Mexico , Iceland , New Zealand , Santiago , Regióetropolitana , Chile , Egypt , Ecuador , World Health Organization , Al Qahirah , Cambridge , Cambridgeshire , Panama , South Korea , Switzerland , Macau , Norway , Malaysia , Lebanon , Colombia , Canada , Guatemala , Jordan , Thailand , Israel , Singapore , Dominican Republic , Saudi Arabia , Peru , Turkey , Great Britain , Russian Federation , American , Mon Jun , Howard Mayer , Ipsen Euronext , Head Of Research , European Commission , Institute Gustave Roussy , American Society Of Clinical Oncology Annual Meeting , European Thyroid Association Guidelines For The Treatment , Head Of Drug Development Department , Ono Pharmaceutical Co , European Union , Takeda Pharmaceutical Company Limited , Bristol Myers Squibb , American Cancer Society , American Society , Clinical Oncology Annual Meeting , Santiago Ponce Aix , Drug Development Department , Executive Vice President , Plus Atezolizumab , With Advanced Non Small Cell Lung Cancer , Previously Treated With , Immune Checkpoint Inhibitor , Results From Cohorts , Cancer Non Small Cell Metastatic , Combination With Atezolizumab , Urothelial Carcinoma , Neck Cancer , United Arabic Emirates , Product Characteristics , Rare Disease , With Specialty Care , Consumer Healthcare , Sponsored Leveli American Depositary Receipt , Forward Looking Statements , French Autorit , Des March , Registration Document , Health Organization , Cancer Journal For , Adv Med , Thyroid Association Guidelines , Advanced Radioiodine Refractory Thyroid , Eur Thyroid , Subjects With Locally Advanced , Metastatic Solid Tumors , Nivolumab Combined With Cabozantinib Compared , Previously Untreated Advanced , Metastatic Renal Cell Carcinoma , Cabozantinib Compared With Placebo , Targeted Therapy , Investor Relations , Relations Manager , Franchise Communicationsoncology , Lipsen , Disco , 022 , Cabometyx , Data , Show , Ncouraging , Results , Monotherapy , Combination , Cross , Different , Humor , Types , Ncluding , Metastatic , Mall , Fell , Young , Dancer ,